AuthorisedTherapeutic use (Phase IV)Interventional

CANIDIAP; CANagliflozin In DIAlysis Patients

This research study, called CANIDIAP, is designed to understand how a medicine named canagliflozin (often known by its brand name, Invokana) works in people who have long-term kidney disease and are on dialysis. Specifically, we're interested in how much of the medicine gets to specific areas within the body where it's supposed to act. This helps us see if the medicine is reaching its target effectively. We'll also compare how it works in people on dialysis who still pass some urine versus those who don't. This information is important for potentially helping doctors find better ways to manage kidney conditions in the future, even though this particular study is focused on how the drug behaves, not whether it’s a new treatment.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Universitair Medisch Centrum Groningen

Enrolment target

Start

23 Feb 2026

Chronic Kidney disease

What is this study about?

This study, called CANIDIAP, is focused on learning more about a medicine called canagliflozin, which you might know as Invokana. It's already approved for treating chronic kidney disease and type 2 diabetes. However, we want to understand exactly how it works in people who have severe kidney disease and are on dialysis.

Think of it like this: medicines need to get to specific 'spots' in your body to do their job. This study is like a detective mission to see how much of the canagliflozin reaches these spots in people on dialysis. This information is really important because it helps doctors understand if the medicine is reaching its target effectively and how well it's being used by the body when kidneys aren't working fully.

We'll also be looking at whether there's a difference in how the medicine works in people on dialysis who still make some urine compared to those who don't make any. All this information helps us build a clearer picture of how canagliflozin works in different situations for people with kidney disease, which can lead to better care in the future. It's a 'Phase IV' study, which means the medicine is already approved for use, and this research helps us learn even more about it.

Key takeaways

This study looks at canagliflozin (Invokana) in people on dialysis.
It aims to see how much of the medicine reaches its targets in the body.
Participation involves taking the study medicine and having regular checks.
It's open to adults aged 18 and older, both men and women, on dialysis.
The information gained could improve future understanding of kidney disease treatment.

Who may be eligible?

To be able to take part in this study, you need to be an adult, aged 18 years or older, with no upper age limit.

This study is open to both men and women. The main condition is that you have ongoing chronic kidney disease and are currently receiving dialysis treatment.

Before you can join, the study team will carefully check your health and medical records to make sure the study is safe and right for you. They will explain everything in detail.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have chronic kidney disease?
Are you currently receiving dialysis treatment?
Are you able to attend clinic visits for assessments?

Answer every question to see your result.

What does participation involve?

If you decide to participate, you would be given the study medicine, 18F-Canagliflozin (Invokana 300 mg tablets). You would likely have a few visits to the clinic for assessments. These assessments will help the study team measure how the medicine is working in your body. This usually involves things like blood tests and special scans to see where the medicine goes. You will be closely monitored by the study team throughout your participation. The total duration of your involvement in the study will be explained to you by the researchers.

Potential risks and benefits

Taking part in this study could help us learn more about how canagliflozin works in people on dialysis, which might lead to better understanding and treatment options in the future. As with any medicine, there's always a chance of side effects, even with an approved drug like Invokana. The study team will explain all known potential risks and monitor you closely. Remember, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is canagliflozin?

Canagliflozin is a medicine, also known as Invokana, used to treat certain conditions including chronic kidney disease and type 2 diabetes.

What is dialysis?

Dialysis is a treatment that cleans your blood when your kidneys are no longer able to do it properly.

Why is this study important?

This study helps us understand exactly how canagliflozin acts in the bodies of people on dialysis, which can improve future care.

Will I get a new treatment if I join?

This study is about understanding how the existing medicine works, not testing a new treatment. The medicine is already approved.

What does 'receptor occupancy' mean?

It's a scientific way of measuring how much of the medicine gets to and 'sticks' to its target areas in your body, showing it's in the right place to do its job.